December 15, 2016 SOURCE: PR NEWSWIRE
Regen BioPharma Inc. (OTCQB: RGBP), (OTCQB: RGBPP) announced today the filing of a [provisional/nonprovisional] utility patent application with the United States Patents and Trademark Office covering NR2F6-silenced CAR T cells. While previous work demonstrated that methodologies developed by Regen and covered under its issued patent #9,091,696 are useful in stimulation of T cell activity, the […]
October 31, 2016 SOURCE: PR NEWSWIRE
Regen BioPharma Inc. (OTCQB: RGBP), (OTCQB: RGBPP) today announced its strategy for developing its novel NR2F6 small molecule modulators. Regen has recently filed a composition of matter patent application covering these novel NR2F6 small molecule modulators.
October 24, 2016 SOURCE: PR NEWSWIRE
Regen BioPharma, Inc., (OTCQB: RGBP) and (OTCQB: RGBPP) announced today that the Pan Am Cancer Treatment Center in Tijuana, Mexico presented final clinical data on their first 5 patients. Beginning in March 2016, 5 patients with chemotherapy-induced bone marrow suppression were treated with HemaXellerate and initial 1 month follow up data were provided. Pan Am […]
October 19, 2016 SOURCE: PR NEWSWIRE
Entest BioMedical’s (OTCPINK: ENTB) wholly owned subsidiary Zander Therapeutics, Inc. announced the filing of a patent application covering composition of matter and methods of use related to molecules identified in their small molecule program that activate and inhibit NR2F6 (‘Small Molecule Modulators of NR2F6 Activity for Animals’).
September 29, 2016 SOURCE: PR NEWSWIRE
Regen BioPharma Inc. (OTCQB: RGBP), (OTCQB: RGBPP) is pleased to announce that Xiaojing Ma, Ph.D. has agreed to serve in the consulting role as the Company’s Senior Research Advisor. Specifically, he will be assisting Dr. Lander in pre-clinical research design and execution of cellular and animal experiments for the Company’s NR2F6 program.
September 22, 2016 SOURCE: REGEN BIOPHARMA INC.
Regen BioPharma Responds to FDA Comments on Its Application for Orphan Drug Designation on its Aplastic Anemia Therapy
September 20, 2016 SOURCE: REGEN BIOPHARMA INC.
Regen BioPharma, Inc. Receives Positive Data From Preclinical Studies of Its Small Molecule NR2F6 Modulators
September 14, 2016 SOURCE: REGEN BIOPHARMA INC.
Regen BioPharma, Inc. Responds to FDA on dCellVax Gene-Silenced Breast Cancer Immunotherapy
August 25, 2016 SOURCE: REGEN BIOPHARMA INC.
Regen BioPharma, Inc. Updates Shareholders on Status of Non-Dilutive Funding Opportunities
August 16, 2016 SOURCE: REGEN BIOPHARMA INC
Regen BioPharma, Inc. Receives New Preliminary HemaXellerate Clinical Data on Bone Marrow Suppression from Pan Am Cancer Treatment Center